19:25 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

VenatoRx reports preclinical data for VNRX-5133 plus cefepime

VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) reported preclinical data from a mouse model of cephalosporin-resistant Klebsiella pneumoniae lung infection showing that VNRX-5133 plus the cephalosporin antibiotic cefepime led to greater reductions in mean bacterial lung titers...
19:04 , Oct 27, 2017 |  BC Week In Review  |  Financial News

China Resources planning China pharma fund

The China Resources Pharmaceutical Equity Investment Fund Management (Shantou) Company Ltd. subsidiary of drug distribution company China Resources Pharmaceutical Group Ltd. (HKSE:3320) proposed to raise RMB2,500 million ($376.8 million) in its China Resources Pharmaceutical Industrial...
18:55 , Oct 27, 2017 |  BC Week In Review  |  Company News

NIH, Geom to conduct Phase I of GT-1

NIH's National Institute of Allergy and Infectious Diseases (NIAID) and Geom Therapeutics Inc. (San Diego, Calif.) partnered to conduct a Phase I trial of Geom's lead candidate GT-1 (LCB10-0200). The double-blind, placebo-controlled, dose-escalation study will...
19:31 , Oct 26, 2017 |  BC Extra  |  Financial News

China Resources planning China pharma fund

The China Resources Pharmaceutical Equity Investment Fund Management (Shantou) Company Ltd. subsidiary of drug distribution company China Resources Pharmaceutical Group Ltd. (HKSE:3320) proposed to raise RMB2,500 million ($376.8 million) in its China Resources Pharmaceutical Industrial...
21:40 , Sep 29, 2017 |  BC Week In Review  |  Company News

Basilea grants China Resources Holdings rights to Zevtera in China

Basilea Pharmaceutica Ltd. (SIX:BSLN) granted the Shenzhen China Resources Gosun Pharmaceutical Co. Ltd. unit of China Resources Holding Co. Ltd. (Wanchai, China) exclusive rights to develop and commercialize antibiotic Zevtera ceftobiprole in China, including Hong...
19:11 , Sep 8, 2017 |  BioCentury  |  Finance

Antibiotic engine

A combination of non-dilutive funding and a newly-raised $31.9 million series B-1 round should give Entasis Therapeutics Inc. enough cash to see its lead candidate all the way through commercialization and to move two others...
21:04 , Nov 11, 2016 |  BC Week In Review  |  Company News

Eli Lilly, Eddingpharm deal

Eli Lilly granted Eddingpharm exclusive rights to promote and distribute antibiotics Ceclor cefaclor and Vancocin vancomycin in mainland China, effective Jan. 1, 2017. Lilly said the deal will enable it to focus resources on its...
00:03 , Nov 11, 2016 |  BC Extra  |  Company News

Lilly grants Eddingpharm antibiotic rights in China

Eli Lilly and Co. (NYSE:LLY) granted Eddingpharm Inc. (Shanghai, China) exclusive rights to promote and distribute antibiotics Ceclor cefaclor and Vancocin vancomycin in mainland China, effective Jan. 1, 2017. Lilly spokesperson Teresa Shewman declined to...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

Basilea, Grupo Biotoscana deal

Basilea granted Grupo Biotoscana exclusive rights to commercialize Cresemba isavuconazole and Zevtera ceftobiprole in 19 Latin American countries, including Argentina, Brazil, Columbia and Mexico. Basilea will receive CHF11 million ($11.3 million) up front...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

AstraZeneca, Pfizer deal

Pfizer will acquire AstraZeneca’s small molecule anti-infectives business. The unit includes approved drugs Zavicefta ceftazidime/ avibactam, Zinforo ceftaroline fosamil and Merrem/Meronem meropenam, as well as Phase II candidates, ATM-AVI and ...